iRemedy’s cover photo
iRemedy

iRemedy

Pharmaceutical Manufacturing

Stuart, Florida 2,751 followers

Rebuilding the medical supply chain through technology, logistics, and direct distribution.

About us

iRemedy is a healthcare technology company headquartered in Stuart, Florida, modernizing the infrastructure that powers global medical supply chains.iRemedy is a healthcare technology company headquartered in Stuart, Florida, modernizing the infrastructure that powers global medical supply chains. Founded by Tony Paquin, at the center is our patented AI platform, MetaCommerceRx™, an intelligent procurement engine that replaces outdated, opaque systems with real-time data, automated workflows, and direct manufacturer-to-provider transactions. Our solutions eliminate friction, reduce cost, and restore visibility across every layer of the healthcare supply ecosystem. By unifying logistics, compliance, and digital commerce into one seamless stack, iRemedy enables medical product companies to scale operations faster and reach new markets without the complexity of legacy intermediaries. From cold chain management to eCommerce automation and digital licensing workflows, we deliver the tools and infrastructure that today's healthcare economy demands. Trusted by manufacturers, hospitals, and government agencies alike, iRemedy is reshaping how healthcare products are distributed, making supply chains smarter, more secure, and more resilient for the future.

Website
https://iremedy.com
Industry
Pharmaceutical Manufacturing
Company size
11-50 employees
Headquarters
Stuart, Florida
Type
Privately Held
Founded
2013
Specialties
Pharmaceutical Distribution, Medical Supply Chain, Healthcare Technology, Wholesale Drug Distribution, Trade Intelligence, Pharmacy Services, Hospital Supply, Government Healthcare, Peptide Distribution, and Made in America Pharmaceuticals

Locations

Employees at iRemedy

Updates

  • There are more drugs in shortage in the United States today than at any point in history. That's not a projection. That's a government-tracked list — and it keeps growing. iRemedy CEO Tony Paquin explains why: the companies that control the healthcare supply chain have little incentive to fix a system that works very well for them. COVID exposed the cracks. The shortage list confirms they haven't been repaired. iRemedy was built to change that. Watch the full clip from Tony's appearance on the Legal Shit Podcast. #HealthcareSupplyChain #DrugShortages #TheEndOfUs #iRemedy

  • Elon Musk is brilliant — but his timelines? Notorious. Big technological visions almost always take longer than the visionary predicts. That's the historical pattern. AI is breaking it. We're not talking years. We're talking months. Sometimes weeks. The pace of change in healthcare supply chain is no longer measured in decades — and that changes everything. 🎙️ Catch the full conversation on SalesPOP! Tony Paquin iRemedy

  • If you want a more reliable healthcare supply chain, start by buying American. iRemedy CEO Tony Paquin makes the case plainly: hospitals and government agencies don't need to overhaul everything overnight — but shifting even a portion of spend toward domestic manufacturers builds resilience that foreign supply chains simply cannot offer. When the next crisis hits, the guy in Indiana is still going to deliver. The factory overseas may not. Watch the full clip from Tony's appearance on the Legal Shit Podcast. #HealthcareSupplyChain #MadeInAmerica #TheEndOfUs #iRemedy

  • When Operation Warp Speed called for 100 million needles and syringes — the government realized almost none were made in America. Tony locked contracts with all 5 factories in China that supplied the entire world. Then the Saudis showed up with SUVs full of gold bullion trying to buy them out. This is what a supply chain crisis actually looks like. 🎙️ The Legal Shit Podcast #HealthcareSupplyChain #MedicalSupplies #OperationWarpSpeed #iRemedy

  • Legislation worth watching for anyone in pharmaceutical supply chain, manufacturing, or healthcare policy. The Biotech Investment National Security Act (BINSA) — introduced by Rep. Moolenaar and Rep. Dingell — would subject U.S. pharmaceutical licensing deals, joint ventures, and equity investments with Chinese entities to Treasury Department national security review for the first time. It covers drug development, biologics manufacturing, and clinical R&D. It also builds on the BIOSECURE Act and new FDA language prohibiting acceptance of Chinese clinical trial data for U.S. drug applications. The numbers behind the legislation: U.S.–China biotech licensing grew from $5B in 2020 to $136B in 2025. iRemedy will continue monitoring developments as this moves through Congress. #PharmaSupplyChain #DomesticManufacturing #PharmaceuticalSecurity #Reshoring #BuyAmericanz

    • No alternative text description for this image
  • AI isn't killing sales — it's separating the order-takers from the real ones. Marketing will automate. Leads will come in without a human touching them. But the rep who can walk into a room, read the situation, and close? That's not going anywhere. Tony Paquin, Co-Founder & CEO of iRemedy, on where the opportunity actually is for salespeople in the age of AI.

  • Drug shortages in the U.S. have reached a historic high — and the consequences are devastating. In this clip from the Legal Shit Podcast, Tony Paquin speaks candidly about who the current system is failing and why that needs to change. This is the conversation the industry needs to be having.

Similar pages

Browse jobs

Funding

iRemedy 4 total rounds

Last Round

Seed

US$ 1.0M

See more info on crunchbase